Free Trial

Journey Medical (DERM) Competitors

Journey Medical logo
$7.11 +0.01 (+0.14%)
As of 04:00 PM Eastern

DERM vs. FBIO, AUTL, STOK, URGN, PHAT, RLAY, ABUS, TNGX, CDXC, and DNTH

Should you be buying Journey Medical stock or one of its competitors? The main competitors of Journey Medical include Fortress Biotech (FBIO), Autolus Therapeutics (AUTL), Stoke Therapeutics (STOK), Urogen Pharma (URGN), Phathom Pharmaceuticals (PHAT), Relay Therapeutics (RLAY), Arbutus Biopharma (ABUS), Tango Therapeutics (TNGX), ChromaDex (CDXC), and Dianthus Therapeutics (DNTH). These companies are all part of the "medical" sector.

Journey Medical vs. Its Competitors

Journey Medical (NASDAQ:DERM) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

In the previous week, Journey Medical had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 1 mentions for Journey Medical and 0 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.00 beat Journey Medical's score of -0.38 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Journey Medical Neutral
Fortress Biotech Neutral

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 15.0% of Journey Medical shares are owned by insiders. Comparatively, 27.9% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Journey Medical has a net margin of -14.76% compared to Fortress Biotech's net margin of -71.24%. Journey Medical's return on equity of -52.03% beat Fortress Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Journey Medical-14.76% -52.03% -11.28%
Fortress Biotech -71.24%-4,712.53%-27.67%

Journey Medical has higher earnings, but lower revenue than Fortress Biotech. Journey Medical is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Journey Medical$56.13M2.95-$14.67M-$0.39-18.23
Fortress Biotech$57.67M0.98-$46M-$2.23-0.86

Journey Medical presently has a consensus price target of $9.50, suggesting a potential upside of 33.61%. Fortress Biotech has a consensus price target of $21.00, suggesting a potential upside of 999.48%. Given Fortress Biotech's higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Journey Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Journey Medical
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Fortress Biotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Journey Medical has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500.

Summary

Journey Medical beats Fortress Biotech on 8 of the 15 factors compared between the two stocks.

Get Journey Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DERM vs. The Competition

MetricJourney MedicalMED IndustryMedical SectorNASDAQ Exchange
Market Cap$165.40M$2.43B$5.53B$9.03B
Dividend YieldN/A1.78%5.24%4.07%
P/E Ratio-18.238.7527.1920.03
Price / Sales2.95641.55414.39108.98
Price / CashN/A21.7726.2128.59
Price / Book7.814.497.925.55
Net Income-$14.67M$31.26M$3.17B$248.49M
7 Day Performance-0.97%1.60%2.18%5.37%
1 Month Performance-3.79%2.46%1.25%6.63%
1 Year Performance36.47%-0.33%33.90%21.20%

Journey Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DERM
Journey Medical
1.8705 of 5 stars
$7.11
+0.1%
$9.50
+33.6%
+36.3%$165.40M$56.13M-18.2390Analyst Downgrade
FBIO
Fortress Biotech
2.1005 of 5 stars
$1.91
+1.6%
$21.00
+999.5%
+6.1%$55.59M$57.67M-0.86170
AUTL
Autolus Therapeutics
2.1039 of 5 stars
$2.26
-4.6%
$9.32
+312.4%
-31.3%$630.76M$10.12M-2.57330
STOK
Stoke Therapeutics
3.985 of 5 stars
$11.69
+1.8%
$23.20
+98.5%
-12.5%$626.77M$36.56M14.80100
URGN
Urogen Pharma
4.4473 of 5 stars
$13.49
-0.7%
$32.86
+143.6%
-15.1%$626.14M$90.40M-4.24200Analyst Forecast
PHAT
Phathom Pharmaceuticals
3.4413 of 5 stars
$8.66
-2.9%
$17.50
+102.1%
-14.9%$622.74M$55.25M-1.65110
RLAY
Relay Therapeutics
2.7682 of 5 stars
$3.55
-2.2%
$17.67
+397.7%
-43.1%$622.34M$10.01M-1.59330Positive News
ABUS
Arbutus Biopharma
1.4257 of 5 stars
$3.14
-3.1%
$5.50
+75.2%
+3.7%$620.55M$6.17M-7.6690
TNGX
Tango Therapeutics
2.2074 of 5 stars
$5.43
-4.7%
$12.20
+124.7%
-33.5%$617.85M$40.99M-4.4590
CDXC
ChromaDex
3.1726 of 5 stars
N/A$9.03
+∞
N/A$611.50M$99.60M787.29120
DNTH
Dianthus Therapeutics
1.794 of 5 stars
$18.25
-3.2%
$53.00
+190.4%
-24.2%$606.22M$6.24M-6.3480Analyst Revision

Related Companies and Tools


This page (NASDAQ:DERM) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners